Cochrane Abstracts
Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Once Versus Twice Daily Low Molecular Weight Heparin for the Initial Treatment of Venous Thromboembolism." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/433574/all/Once_versus_twice_daily_low_molecular_weight_heparin_for_the_initial_treatment_of_venous_thromboembolism.
Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433574/all/Once_versus_twice_daily_low_molecular_weight_heparin_for_the_initial_treatment_of_venous_thromboembolism. Accessed December 9, 2024.
Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433574/all/Once_versus_twice_daily_low_molecular_weight_heparin_for_the_initial_treatment_of_venous_thromboembolism
Once Versus Twice Daily Low Molecular Weight Heparin for the Initial Treatment of Venous Thromboembolism [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 December 09]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/433574/all/Once_versus_twice_daily_low_molecular_weight_heparin_for_the_initial_treatment_of_venous_thromboembolism.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism
ID - 433574
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/433574/all/Once_versus_twice_daily_low_molecular_weight_heparin_for_the_initial_treatment_of_venous_thromboembolism
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
